Jeff Yass’s Autolus Therapeutics AUTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$257K Sell
132,727
-44,505
-25% -$85K ﹤0.01% 11328
2026
Q2
$284K Sell
177,232
-221,911
-56% -$348K ﹤0.01% 11177
2026
Q1
$551K Sell
399,143
-199,844
-33% -$304K ﹤0.01% 9409
2025
Q4
$1.19M Buy
598,987
+363,159
+154% +$558K ﹤0.01% 6791
2025
Q3
$384K Buy
235,828
+15,259
+7% +$29.8K ﹤0.01% 9566
2025
Q2
$503K Buy
220,569
+153,514
+229% +$254K ﹤0.01% 9166
2025
Q1
$104K Sell
67,055
-3,836
-5% -$7.79K ﹤0.01% 11516
2024
Q4
$167K Buy
70,891
+50,187
+242% +$170K ﹤0.01% 10930
2024
Q3
$75.2K Buy
20,704
+301
+1% +$1.2K ﹤0.01% 11198
2024
Q2
$71K Sell
20,403
-50,816
-71% -$219K ﹤0.01% 11239
2024
Q1
$454K Buy
71,219
+18,215
+34% +$114K ﹤0.01% 8731
2023
Q4
$341K Buy
+53,004
New +$202K ﹤0.01% 9557
2023
Q2
– Sell
-38,947
Closed -$92.4K – 12031
2023
Q1
$71.7K Buy
38,947
+18,744
+93% +$36.6K ﹤0.01% 11518
2022
Q4
$38.4K Buy
20,203
+8,063
+66% +$20.4K ﹤0.01% 11534
2022
Q3
$26K Sell
12,140
-4,477
-27% -$13.3K ﹤0.01% 12505
2022
Q2
$47K Buy
+16,617
New +$50.6K ﹤0.01% 12008
2022
Q1
– Sell
-15,670
Closed -$65.9K – 12944
2021
Q4
$81K Buy
+15,670
New +$94K ﹤0.01% 12274

Other funds holding AUTL

Jeff Yass's AUTL Position: Q3 2026 in Review

Jeff Yass reduced its Autolus Therapeutics (AUTL) stake by 25% in Q3 2026, selling an estimated $85K and leaving 132,727 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #11328.

Jeff Yass first reported a position in AUTL in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.19M in Q4 2025. 90 funds tracked by Wall St. Rank hold AUTL as of Q3 2026.

  • Jeff Yass held 132,727 shares of Autolus Therapeutics worth $257K as of Q3 2026.
  • Jeff Yass sold 44,505 Autolus Therapeutics shares in Q3 2026, an estimated $85K.
  • Autolus Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #11328 holding.
  • Jeff Yass first reported a position in Autolus Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Jeff Yass's Autolus Therapeutics position peaked at $1.19M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.